3 completed. 3 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Completed 3 |
| Phase 1 | 1 | Completed 1 |
Follow Frequency Therapeutics: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| FX-322 in Adults With Acquired Sensorineural Hearing Loss FX-322, Placebo - Hearing Loss, Sensorineural, Noise Induced Hearing Loss | Phase 2 | Completed | Frequency Therapeutics | 142 | 2021-10-12 | 2023-04-21 |
| FX-322 in Adults With Stable Sensorineural Hearing Loss FX-322 (One Dose), FX-322 (Two Doses), FX-322 (Four Doses) - Sensorineural Hearing Loss, Noise Induced Hearing Loss | Phase 2 | Completed | Frequency Therapeutics | 95 | 2019-10-04 | 2023-04-27 |
| FX-322 in Sensorineural Hearing Loss FX-322, Placebo - Sensorineural Hearing Loss | Phase 1 / Phase 2 | Completed | Frequency Therapeutics | 23 | 2018-07-03 | 2022-11-14 |
Hearing Loss, Sensorineural (3) · Hearing Loss, Noise-Induced (2) · Hearing Loss, Sudden (2)
United States (3)
Carl LeBel, PhD (2) · George Atiee, MD (1)